
Regeneron's Livsayis (cemdisiran) gains FDA approval for adults with antibody-positive generalized myasthenia gravis, dosed four times a year.
View the Pharmaceutical Executive December 2025 issue in an interactive format.
Click
11 months ago
A Year of Change11 months ago
Brent Saunders: Eyeing New Horizons11 months ago
The GLP-1 Gold Rush11 months ago
A Defining Period for M&A11 months ago
Is Manufacturing Coming Home?11 months ago
DTC Models and Momentum11 months ago
The Cost of Fixing Pharma





